Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Treating and preventing the lethal metastatic spread of childhood brain cancer.

EF 2019-20

Résumé
"Every year, hundreds of parents hear the words, ""Your child has brain cancer"" and behind every concerned family is a scared child who doesn't understand what is happening to them. The leading cause of death for paediatric oncology patients is malignant brain tumours; medulloblastoma (MB) is the most common and patients are often faced with a grim prognosis. However, the fatal nature of MB does not arise from the primary tumour itself, but rather from the metastases which are biologically distinct. As such, the same treatment that could work on the tumour is not effective against the metastases. Despite the urgent need for treatment innovation, there are currently no FDA-approved drugs available to treat these metastases, nor are there promising candidates in clinical trial. In an effort to combat the high patient mortality rates in this population, my project will focus on the metastatic component of MB, specifically on the role of CCL2 and its receptor CCR2—which are involved in mediating the passage of immune cells at the blood-brain-barrier—and whether this aids MB metastasis to propagate. Previous findings from our lab demonstrate that elevated CCL2 expression drives metastasis and other groups have also shown that CCL2-inhibitory drugs have been effective in treating both multiple sclerosis and metastatic breast cancer in clinical trials. Thus, I will be investigating the relationship between CCL2/CCR2 in three ways: by employing patient samples and genetically-modified CCL2 mice to define a mechanistic approach; by determining the genomic differences in circulating tumour cells from humans and mice with MB; and by testing a range of new FDA-approved drugs to block CCL2/CCR2 in MB models to determine if the prevention and treatment of MB metastasis is possible."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
429028
Name
Sirbu Olga I
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Treating and preventing the lethal metastatic spread of childhood brain cancer.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biological And Biochemical Mechanisms; Biomedical Aspects Of Human Health; Cancer Genetics; Cell Signalling; Molecular Biology; Neurosciences; Pediatric Medulloblastoma; Statistics And Evaluation; Stem Cells
Abstract
"Every year, hundreds of parents hear the words, ""Your child has brain cancer"" and behind every concerned family is a scared child who doesn't understand what is happening to them. The leading cause of death for paediatric oncology patients is malignant brain tumours; medulloblastoma (MB) is the most common and patients are often faced with a grim prognosis. However, the fatal nature of MB does not arise from the primary tumour itself, but rather from the metastases which are biologically distinct. As such, the same treatment that could work on the tumour is not effective against the metastases. Despite the urgent need for treatment innovation, there are currently no FDA-approved drugs available to treat these metastases, nor are there promising candidates in clinical trial. In an effort to combat the high patient mortality rates in this population, my project will focus on the metastatic component of MB, specifically on the role of CCL2 and its receptor CCR2—which are involved in mediating the passage of immune cells at the blood-brain-barrier—and whether this aids MB metastasis to propagate. Previous findings from our lab demonstrate that elevated CCL2 expression drives metastasis and other groups have also shown that CCL2-inhibitory drugs have been effective in treating both multiple sclerosis and metastatic breast cancer in clinical trials. Thus, I will be investigating the relationship between CCL2/CCR2 in three ways: by employing patient samples and genetically-modified CCL2 mice to define a mechanistic approach; by determining the genomic differences in circulating tumour cells from humans and mice with MB; and by testing a range of new FDA-approved drugs to block CCL2/CCR2 in MB models to determine if the prevention and treatment of MB metastasis is possible."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sirbu, Olga I
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~